2014-03-14 08:41:01 - ELI LILLY - Relief from Tax rate but Unsustainable Beyond 2013 Due to High Impact Cymbalta Loss - a new market research report on companiesandmarkets.com
LLY reported its Q4-2012 financial results 2012 which is in-line with our expectation. The increased 2013 EPS guidance is mainly due to the potential R&D tax credit which will be realized from 1Q 2013. But beyond 2013, we see loss of Cymbalta sales to generic competition as painful. Assuming the same level of R&D expense going forward, Cymbalta loss can knock off more than 50 percent of LLY´s current cash flows.
The R&D pipeline continues to be fickle and we look at the recent long term guidance issued by LLY with caution. A major cut in R&D expense seems to be the only way that LLY can meet expectations inbuilt in the current price. Despite the increasing growth of diabetes therapy,
the revenues from Humulin and Humalog continued to be flat due to competition
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.